Study to Assess the Efficacy and Safety of Orismilast in Psoriasis

NCT05190419 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Skin Diseases

Interventions

DRUG: Orismilast modified release tablets
DRUG: Placebo

Sponsor

UNION therapeutics